The Company is reaffirming full-year 2025 revenue guidance of $224 million to $230 million, representing growth of 7% to 10%, compared to full-year 2024. The Company continues to expect breakeven Adjusted EBITDA for the full-year 2025
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) – June 10, 2025 Deadline to Join – Contact Levi & Korsinsky LLP
- Treace Medical price target lowered to $14 from $16 at BTIG
- Treace Medical price target lowered to $8 from $9.50 at Truist
- Treace Medical Concepts CEO to Become Board Chairman
- Treace Medical appoints John Treace as chairman of the board